These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 31997435)
1. Protease-activated receptor-2 accelerates intestinal tumor formation through activation of nuclear factor-κB signaling and tumor angiogenesis in Apc Kawaguchi M; Yamamoto K; Kataoka H; Izumi A; Yamashita F; Kiwaki T; Nishida T; Camerer E; Fukushima T Cancer Sci; 2020 Apr; 111(4):1193-1202. PubMed ID: 31997435 [TBL] [Abstract][Full Text] [Related]
2. Hepatocyte growth factor activator inhibitor type 1 is a suppressor of intestinal tumorigenesis. Hoshiko S; Kawaguchi M; Fukushima T; Haruyama Y; Yorita K; Tanaka H; Seiki M; Inatsu H; Kitamura K; Kataoka H Cancer Res; 2013 Apr; 73(8):2659-70. PubMed ID: 23447577 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of nuclear factor-κB signaling suppresses Spint1-deletion-induced tumor susceptibility in the ApcMin/+ model. Kawaguchi M; Yamamoto K; Kanemaru A; Tanaka H; Umezawa K; Fukushima T; Kataoka H Oncotarget; 2016 Oct; 7(42):68614-68622. PubMed ID: 27612426 [TBL] [Abstract][Full Text] [Related]
4. Hepatocyte growth factor activator inhibitor type 1 regulates epithelial to mesenchymal transition through membrane-bound serine proteinases. Cheng H; Fukushima T; Takahashi N; Tanaka H; Kataoka H Cancer Res; 2009 Mar; 69(5):1828-35. PubMed ID: 19223533 [TBL] [Abstract][Full Text] [Related]
5. Protease-activated Receptor-2 (PAR-2)-mediated Nf-κB Activation Suppresses Inflammation-associated Tumor Suppressor MicroRNAs in Oral Squamous Cell Carcinoma. Johnson JJ; Miller DL; Jiang R; Liu Y; Shi Z; Tarwater L; Williams R; Balsara R; Sauter ER; Stack MS J Biol Chem; 2016 Mar; 291(13):6936-45. PubMed ID: 26839311 [TBL] [Abstract][Full Text] [Related]
6. Membrane-bound serine protease inhibitor HAI-1 is required for maintenance of intestinal epithelial integrity. Kawaguchi M; Takeda N; Hoshiko S; Yorita K; Baba T; Sawaguchi A; Nezu Y; Yoshikawa T; Fukushima T; Kataoka H Am J Pathol; 2011 Oct; 179(4):1815-26. PubMed ID: 21840293 [TBL] [Abstract][Full Text] [Related]
7. Regulation of pericellular proteolysis by hepatocyte growth factor activator inhibitor type 1 (HAI-1) in trophoblast cells. Kohama K; Kawaguchi M; Fukushima T; Lin CY; Kataoka H Hum Cell; 2012 Dec; 25(4):100-10. PubMed ID: 23248048 [TBL] [Abstract][Full Text] [Related]
8. Hepatocyte growth factor activator inhibitor type 1 maintains the assembly of keratin into desmosomes in keratinocytes by regulating protease-activated receptor 2-dependent p38 signaling. Kawaguchi M; Kanemaru A; Sawaguchi A; Yamamoto K; Baba T; Lin CY; Johnson MD; Fukushima T; Kataoka H Am J Pathol; 2015 Jun; 185(6):1610-23. PubMed ID: 25842366 [TBL] [Abstract][Full Text] [Related]
9. Deregulated matriptase activity in oral squamous cell carcinoma promotes the infiltration of cancer-associated fibroblasts by paracrine activation of protease-activated receptor 2. Kanemaru A; Yamamoto K; Kawaguchi M; Fukushima T; Lin CY; Johnson MD; Camerer E; Kataoka H Int J Cancer; 2017 Jan; 140(1):130-141. PubMed ID: 27615543 [TBL] [Abstract][Full Text] [Related]
10. Insufficiency of hepatocyte growth factor activator inhibitor-1 confers lymphatic invasion of tongue carcinoma cells. Izumi A; Yamamoto K; Kawaguchi M; Yamashita F; Fukushima T; Kiwaki T; Tanaka H; Yamashita Y; Kataoka H Cancer Sci; 2022 Jun; 113(6):2179-2193. PubMed ID: 35332604 [TBL] [Abstract][Full Text] [Related]
11. Loss of hepatocyte growth factor activator inhibitor type 1 participates in metastatic spreading of human pancreatic cancer cells in a mouse orthotopic transplantation model. Ye J; Kawaguchi M; Haruyama Y; Kanemaru A; Fukushima T; Yamamoto K; Lin CY; Kataoka H Cancer Sci; 2014 Jan; 105(1):44-51. PubMed ID: 24147538 [TBL] [Abstract][Full Text] [Related]
12. Defect of hepatocyte growth factor activator inhibitor type 1/serine protease inhibitor, Kunitz type 1 (Hai-1/Spint1) leads to ichthyosis-like condition and abnormal hair development in mice. Nagaike K; Kawaguchi M; Takeda N; Fukushima T; Sawaguchi A; Kohama K; Setoyama M; Kataoka H Am J Pathol; 2008 Nov; 173(5):1464-75. PubMed ID: 18832587 [TBL] [Abstract][Full Text] [Related]
13. Loss of matriptase suppression underlies spint1 mutation-associated ichthyosis and postnatal lethality. Szabo R; Kosa P; List K; Bugge TH Am J Pathol; 2009 Jun; 174(6):2015-22. PubMed ID: 19389929 [TBL] [Abstract][Full Text] [Related]
14. Activated protein C prevents glutamate- and thrombin-induced activation of nuclear factor-kappaB in cultured hippocampal neurons. Gorbacheva L; Pinelis V; Ishiwata S; Strukova S; Reiser G Neuroscience; 2010 Feb; 165(4):1138-46. PubMed ID: 19931359 [TBL] [Abstract][Full Text] [Related]
15. Expression of serine peptidase inhibitor Kunitz type 1 in differentiated thyroid cancer. Liu CL; Yang PS; Chien MN; Chang YC; Lin CH; Cheng SP Histochem Cell Biol; 2018 Jun; 149(6):635-644. PubMed ID: 29532159 [TBL] [Abstract][Full Text] [Related]
17. Deoxycholic acid activates epidermal growth factor receptor and promotes intestinal carcinogenesis by ADAM17-dependent ligand release. Dong W; Liu L; Dou Y; Xu M; Liu T; Wang S; Zhang Y; Deng B; Wang B; Cao H J Cell Mol Med; 2018 Sep; 22(9):4263-4273. PubMed ID: 29956475 [TBL] [Abstract][Full Text] [Related]
18. Heterozygous deletion of ATG5 in Apc(Min/+) mice promotes intestinal adenoma growth and enhances the antitumor efficacy of interferon-gamma. Wang L; Wang Y; Lu Y; Zhang Q; Qu X Cancer Biol Ther; 2015; 16(3):383-91. PubMed ID: 25695667 [TBL] [Abstract][Full Text] [Related]